Virogin Biotech Announces Dosing the First US Patient in a Phase 1 Study of VG201 for Patients With Advanced Solid Tumors

VANCOUVER, British Columbia, November 15, 2022 (Newswire.com) – Virogin Biotech, a clinical-stage biotech company, today announced that the first patient has been dosed in its Phase 1 clinical study evaluating VG201, a first-in-class HSV Type I oncolytic virus product constructed based on a transcriptional and translational dual-regulated (TTDR) backbone developed by Virogin Biotech. It is designed […]

Virogin Biotech and MD Anderson Announce Strategic Collaboration to Accelerate Oncolytic Virus Research and Development for Treating Advanced Cancers

VANCOUVER, British Columbia & HOUSTON, September 8, 2022 (Newswire.com) – Virogin Biotech, a clinical-stage biotech company, and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to accelerate the development of investigational treatments, including oncolytic viruses and immunotherapies, for patients with advanced cancers.  The agreement brings together MD Anderson’s clinical trials expertise and infrastructure […]

Virogin Biotech Receives IND Approval from the U.S. FDA for VG201

Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company is pleased to announce that their Investigational New Drug (IND) application for VG201 has been granted by the U.S. Food and Drug Administration (FDA), allowing Virogin to initiate a Phase I clinical trial of VG201. VG201 is Virogin’s first product candidate built with Transcriptional and Translational […]

Virogin Biotech Receives IND Approvals from Chinese NMPA for VG201 and VG161

Vancouver, Canada – Virogin Biotech, a clinical-stage biotech company, is pleased to announce that, on April 19, 2022, the National Medical Products Administration (NMPA), the Chinese agency for regulating drugs and medical devices, granted IND approvals for the company’s investigational drug candidates VG201 and VG161, allowing the initiation of a Phase I clinical trial of […]